Form Health的封面图片
Form Health

Form Health

医院和医疗保健

Boston,Massachusetts 5,631 位关注者

Form Health is the national leader in science-based obesity care.

关于我们

Form Health is the national leader in science-based obesity and cardiometabolic care. Our clinical care model consists of one-on-one, personalized care from a dedicated ABOM-certified physician and a CSOWM-certified Registered Dietitian, who develop individualized treatment plans that address behavioral health, nutrition, physical activity, and include a prescription for FDA-approved medication, if appropriate. Form Health keeps safety, efficacy, and outcomes at the forefront as we incorporate the latest research and science into our approach. This means we’re always innovating, constantly getting smarter about the science of obesity care, relentlessly focusing on exceptional results, and calling out harmful practices that hold back progress. The result is life-changing outcomes for our patients and meaningful ROI for our enterprise partners. Form Health is in-network with national health plans. Learn more at formhealth.co.

网站
https://formhealth.co
所属行业
医院和医疗保健
规模
51-200 人
总部
Boston,Massachusetts
类型
私人持股
创立
2019

地点

  • 主要

    109 State St

    5th Floore

    US,Massachusetts,Boston,02109

    获取路线

Form Health员工

动态

  • 查看Form Health的组织主页

    5,631 位关注者

    Director of Clinical Nutrition, Julia Axelbaum, RD, CSOWM emphasizes the importance of working with a Registered Dietitian when taking a GLP-1 medication. As patients eat less, nutrition choices become even more important. Registered Dietitians provide expert guidance to help individuals navigate a complex food environment and set themselves up for long-term success. At Form Health, we take a comprehensive, science-based approach to preventing and managing obesity while achieving positive health outcomes. Our patients receive 1:1 personalized care from an ABOM physician and CSOWM Registered Dietitian. Together, they create individualized treatment plans tailored to each patient’s unique needs, focusing on behavioral health, nutrition, physical activity, and including a prescription for FDA-approved medication, when appropriate. Ready to take a proactive approach to managing employee health while reducing the long-term costs associated with obesity and its related cardiometabolic conditions? Email [email protected] to learn more.

    查看Julia Axelbaum, RD, CSOWM的档案

    Registered Dietitian, Obesity and Weight Management Specialist

    GLP-1 medications are transforming how people approach their eating habits and reshaping the food landscape. Many individuals report fewer cravings for ultra-processed foods and a greater preference for fresh, whole-food options. With smaller appetites and eating less, it's even more crucial to focus on what foods are being chosen. Given the overwhelming and often confusing food marketing out there, it can be hard to know what’s truly “healthy.” This is where Registered Dietitians come in. They guide patients through food labels, decipher health claims, and help make informed choices that support both weight loss and long-term health. Prioritizing the right foods, not just eating less food, is essential for preserving muscle mass, ensuring balanced nutrition, and achieving lasting success.

  • 查看Form Health的组织主页

    5,631 位关注者

    Chief Medical Officer Florencia Halperin shares how our unique care model drives real results—helping patients achieve long-term success and improved health. At Form Health, we take a comprehensive, science-based approach to managing obesity and cardiometabolic conditions to improve health outcomes. Our patients receive personalized, one-on-one care from an ABOM-certified physician and a CSOWM-certified Registered Dietitian. Together, they develop tailored treatment plans that address each patient’s unique needs, focusing on behavioral health, nutrition, physical activity, and, when appropriate, including a prescription for FDA-approved medication. Looking to take a proactive approach to employee health while reducing the long-term costs associated with obesity and related cardiometabolic conditions? Email [email protected] to learn more.

  • 查看Form Health的组织主页

    5,631 位关注者

    Happy National Registered Dietitians Day! ?? Today, we celebrate the incredible Registered Dietitians at Form Health who guide and support our patients in making lasting lifestyle changes that improve health outcomes and overall well-being. Through their expertise, encouragement, and compassionate care, they help transform lives, one change at a time.?

    • 该图片无替代文字
  • 查看Form Health的组织主页

    5,631 位关注者

    The celebration of our "Fierce 15" recognition continues! Seeing Form Health on the NYSE floor is exciting and a reminder of the impact we’re making in the rapidly evolving obesity medicine space. We're honored to be recognized for our commitment to changing lives through science-based, compassionate obesity care.

    • 该图片无替代文字
    • 该图片无替代文字
  • 查看Form Health的组织主页

    5,631 位关注者

    A lot is happening in the world of obesity medicine right now. Form Health’s CMO, Florencia Halperin, reviews the latest changes and shares her thoughts on what they mean for the future. For employers evaluating obesity treatment solutions, it’s essential to partner with an organization that stays at the forefront of scientific advancements and applies the latest evidence to personalized treatment plans Form Health offers a proven, science-backed obesity solution that delivers sustainable weight loss, improved health outcomes, and reduced costs. Contact us at [email protected] to learn more.

    查看Florencia Halperin的档案

    Chief Medical Officer, Form Health

    Things are changing so quickly in the realm of obesity medicine! ?? 10 days ago, the only lower-priced cash pay option for obesity management medications was through Lilly Direct, and only the 2 lowest doses of Zepbound (tirzepatide) were available, through a vial and syringe injection method. ?? Last week, Eli Lilly announced an expansion of their program, so that now 2.5, 5, 7.5 and 10 mg doses are available. ?? This week, Novo Nordisk released a cash pay program for all doses of their Wegovy (semaglutide) pens, through NovoCare pharmacy. ?? Both options cost around $500/month, contrasting with about $1200 in standard pharmacies. This is also still a lot of money for most people to pay out of pocket for a medication, one that they need to treat a metabolic disease. Perhaps these lower-priced options will be forcing functions that lead to more widespread price changes. And one thing is for sure, if anyone has hundreds of dollars to spend per month on obesity treatment, choosing an FDA-regulated branded product is much safer than a compounded knock-off. So this is progress and promise on multiple fronts! https://lnkd.in/eGy2uQhb

  • 查看Form Health的组织主页

    5,631 位关注者

    Form Health is proud to be presenting as an Alumni member at World 50 Accelerator Spring 2025 Employer Benefits Accelerator Roundtable. We'll be sharing the latest about our science-based approach to total weight and cardiometabolic care and sharing how we've worked with EHIR members to implement benefits programs that provide access to physician-led care that drives weight loss and improved cardiometabolic health while controlling costs. Let us share how Form Health can help your organization provide a proven obesity solution that applies the latest evidence to deliver sustainable weight loss, improved health, and cost savings. Contact us at [email protected] to learn more.

    查看World 50 Accelerator的组织主页

    8,257 位关注者

    ??Breakthrough Alert: Innovators Redefining Employer Benefits! This week, we’re bringing together 25 of the most groundbreaking healthcare and workplace solutions that are transforming how companies support their most valuable asset - their people. From AI-powered health navigation to revolutionary benefits platforms, these innovators are solving complex challenges with razor-sharp precision. Get ready to witness the future of workplace wellness, benefits optimization, and employee support. These companies aren’t just thinking outside the box - they’re redesigning the box entirely. Our exclusive member roundtables are where cutting-edge meets real-world impact. The future of work starts here. ?? ?? 9amHealth, Abett, Aligned Marketplace, BeneRe, Betr , Bluespine, Complement 1 Health, finHealth, Form Health, Function Health, Galileo , nudge, Oshi Health, Papa, Paytient, Reclaim Health, ROAR Forward, Scripta Insights, SmartLight Analytics, SmithRx, Truveris, When, Workpartners #FutureOfWork #HealthTech #InnovationEcosystem #EmployerBenefits

    • 该图片无替代文字
  • 查看Form Health的组织主页

    5,631 位关注者

    Today, on #WorldObesityDay, Form Health reaffirms our mission to transform lives through science-based, compassionate obesity care. Our team is dedicated to helping make bias-free clinical obesity treatment accessible to everyone who needs it. Patients with obesity deserve care that is safe, effective, and sustainable; just like patients with any other chronic medical condition. Obesity care is life-changing - it's not just about weight loss, but also supports long-term health and well-being. Let us help your organization implement a comprehensive clinical obesity solution that transforms your members' lives while managing costs. Contact [email protected] to learn more

    • 该图片无替代文字
  • 查看Form Health的组织主页

    5,631 位关注者

    We are proud to announce that Form Health has been named by Fierce Healthcare as one of 2025’s “Fierce 15” healthcare companies! This recognition reflects the hard work of our dedicated team and underscores the significant progress we’ve made in expanding access to science-based total weight and cardiometabolic care. Since our founding in 2019, we’ve been committed to following the science and supporting our patients with a comprehensive approach that includes behavioral health, nutrition, and physical activity, alongside FDA-approved weight loss medication when appropriate. We always keep safety, efficacy, and outcomes at the forefront as we incorporate the latest research and science into our approach. The result is life-changing outcomes for our patients and meaningful ROI for our enterprise partners. There’s been a paradigm shift in how obesity, overweight, and cardiometabolic disease is treated and Form’s personalized and comprehensive care model has clearly resonated, with major employers and tens of thousands of patients across the United States choosing Form as their obesity medicine provider. We are excited to continue expanding our reach and bringing our industry-leading approach to even more Americans who need it.? Thank you to Fierce Healthcare for this honor! Check out the full list below.

  • 查看Form Health的组织主页

    5,631 位关注者

    CMO Florencia Halperin provides an update on how the recent FDA ruling will impact the future of compounded GLP-1 medications. The good news: The ruling prioritizes patient safety by restricting access to dangerous, unregulated medications. However, there is still work to be done to improve access to science-based obesity treatment including FDA-approved medications. At Form Health, we are committed to providing safe and effective science-based obesity care. That’s why we only prescribe FDA-approved medications, when clinically appropriate. Let us demonstrate how we can help your organization offer clinical obesity care that transforms members lives and delivers ROI while always prioritizing patient safety. Contact us at [email protected] to learn more.

    查看Florencia Halperin的档案

    Chief Medical Officer, Form Health

    The FDA has issued an announcement that state-licensed pharmacies (503A) have until April 22 to stop selling compounded semaglutide, and 503B pharmacies have until May 22. This came about in part because after almost exactly 3 years, the FDA is able to declare that semaglutide --the GLP-1 agonist for treatment of diabetes (Ozempic) and obesity (Wegovy)--is no longer in shortage. Neither is tirzepatide (Mounjaro/Zepbound). These firm regulatory announcements with specific deadlines are really a step in the right direction! ?? But we have to wait and see what will actually happen to sales of compounded obesity products. The financial pulls are so powerful that companies that sell unapproved compounds are already looking for other loopholes to exploit -- so they can continue their concerning but profitable practices. ?? For example, compounding medications for specific individual medical needs is allowable, even without shortages, which is intended for patients who cannot take what is commercially available. In reference to this, companies are already touting their products as "personalized treatments" (when the reality is most don't even offer a real medical visit to understand the person before dispensing the drug products!). ?? I hope the FDA enforces its new mandates and helps us safeguard the health of Americans with obesity. But part of this is also a bigger issue - if Americans had reliable access to safe, effective, evidence-based care for their metabolic disease, then they would not need to turn to cash pay options that lack clinical trial testing. We have to continue to work to expand that access, and make sure every patient who needs it can get the kind of compassionate, comprehensive, expert care we provide at Form Health!

相似主页

查看职位

融资